It has been suggested that metformin affects miR-155-5p by inhibiting the Toll-like receptor 4/nuclear factor kappa-light-chain-enhancer of activated B cells (TLR4/NF-κB) axis, potentially reducing the production of proinflammatory cytokines and slowing DKD progression [74]. Here, NFKB1 is linked to diabetic kidney disease.